U.S. patent application number 10/199057 was filed with the patent office on 2003-02-13 for rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders.
This patent application is currently assigned to Angelika Esswein, Wolfgang Schaefer, and Konrad Honold. Invention is credited to Esswein, Angelika, Honold, Konrad, Kaluza, Klaus, Schaefer, Wolfgang, Tsaklakidis, Christos.
Application Number | 20030032813 10/199057 |
Document ID | / |
Family ID | 8232720 |
Filed Date | 2003-02-13 |
United States Patent
Application |
20030032813 |
Kind Code |
A1 |
Esswein, Angelika ; et
al. |
February 13, 2003 |
Rhodanine carboxylic acid derivatives for the treatment and
prevention of metabolic bone disorders
Abstract
1 Compounds of general formula (I), where m is 0-8, q is 0-8, a
is between 0-4, A signifies a single or double bond, R.sub.1 and
R.sub.2 signify hydrogen or lower alkyl, whereby R.sub.1 and
R.sub.2 are the same or different and, when m signifies 2-8,
R.sub.1 and R.sub.2 in the group CR.sub.1.dbd.CR.sub.2 can have
various significances, R.sub.3 signifies hydrogen or lower alkyl, X
signifies hydrogen or --(CH.sub.2).sub.b--COR.- sub.4 with b=0-4, Y
signifies hydrogen, --COR.sub.4, phenyl or indolyl residue, R.sub.4
signifies hydroxyl, lower alkoxy or the NR.sub.1R.sub.2 residue,
whereby R.sub.1 and R.sub.2 are the same or different, W is
optionally mono- or polysubstituted saturated or unsaturated mono-,
bi- or tricycle which can contain one or more hetero atoms, as well
as physiologically compatible salts, esters, optically active
forms, racemates, tautomers, derivatives which can be metabolized
in vivo to compounds of general formula (I), and produces
medicaments for prophylaxis or therapy of metabolic bone disorders
with the compounds.
Inventors: |
Esswein, Angelika;
(Buttelborn, DE) ; Schaefer, Wolfgang; (Mannhiem,
DE) ; Tsaklakidis, Christos; (Weinheim, DE) ;
Honold, Konrad; (Penzberg, DE) ; Kaluza, Klaus;
(Bad Heilbrunn, DE) |
Correspondence
Address: |
ARENT FOX KINTNER PLOTKIN & KAHN, PLLC
SUITE 600
1050 CONNECTICUT AVENUE, N.W.
WASHINGTON
DC
20036-5339
US
|
Assignee: |
Angelika Esswein, Wolfgang
Schaefer, and Konrad Honold
|
Family ID: |
8232720 |
Appl. No.: |
10/199057 |
Filed: |
July 22, 2002 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10199057 |
Jul 22, 2002 |
|
|
|
09787917 |
Jun 21, 2001 |
|
|
|
Current U.S.
Class: |
548/183 |
Current CPC
Class: |
A61P 19/00 20180101;
C07D 493/04 20130101; C07D 277/20 20130101; C07D 417/12 20130101;
C07D 277/36 20130101; C07D 417/06 20130101 |
Class at
Publication: |
548/183 ;
514/369 |
International
Class: |
A61K 031/426; A61K
031/427; C07D 417/02 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 30, 1998 |
EP |
98118493.0 |
Sep 30, 1999 |
PCT/EP99/07248 |
Claims
1. Use of compounds of general formula (I) 7in which m signifies a
number between 0-8, q signifies a number between 0-8 a signifies a
number between 0-4 A signifies a single or double bond R.sub.1,
R.sub.2 signify hydrogen or lower alkyl, whereby R.sub.1 and
R.sub.2 can be the same or different and, when m signifies 2-8,
R.sub.1 and R.sub.2 in the group CR.sub.1.dbd.CR.sub.2 can have
various significances within the following sequence R.sub.3
signifies hydrogen or lower alkyl X signifies hydrogen or
--(CH.sub.2).sub.b--COR.sub.4 with b=0-4 Y signifies hydroxyl,
--COR.sub.4, phenyl or indolyl residue R.sub.4 signifies hydroxyl,
lower alkoxy or the NR.sub.1R.sub.2 residue, whereby R.sub.1 and
R.sub.2 can be the same or different W signifies an optionally
mono- or polysubstituted saturated or unsaturated mono-, bi- or
tricycle which can contain one or more hetero atoms, for the
preparation of medicaments for the treatment and prevention of
metabolic bone disorders,
2. Compounds of general formula (I) 8in which m signifies a number
between 0-8, q signifies a number between 0-8 a signifies a number
between 0-4 A signifies a single or double bond R.sub.1, R.sub.2
signify hydrogen or lower alkyl, whereby R.sub.1 and R.sub.2 can be
the same or different and, when m signifies 2-8, R.sub.1 and
R.sub.2 in the group CR.sub.1.dbd.CR.sub.2 can have various
significances within the following sequence R.sub.3 signifies
hydrogen or lower alkyl X signifies hydrogen or
--(CH.sub.2).sub.b--COR.sub.4 with b=0-4 Y signifies hydroxyl,
--COR.sub.4, phenyl or indolyl residue R.sub.4 signifies hydroxyl,
lower alkoxy or the NR.sub.1R.sub.2 residue, whereby R.sub.1 and
R.sub.2 can be the same or different W signifies an optionally
mono- or polysubstituted saturated or unsaturated mono-, bi- or
tricycle which can contain one or more hetero atoms, whereas W is
not phenyl or indolyl, if m and g are both 0, R.sub.3, is hydrogen
and A is a double bond, as well as their physiologically compatible
salts, esters, optically active forms, racemates, tautomers, as
well as derivatives which can be metabolized in vivo to compounds
of general formula (I)
3. Medicament containing at least one compound of general formula
(I) according to claim 2 in admixture with usual pharmaceutical
adjuvents and carrier material
Description
[0001] The present invention is concerned with rhodanine carboxylic
acid derivatives for the treatment and prevention of metabolic bone
disorders, a process for their manufacture as well as medicaments
which contain these compounds.
[0002] In healthy persons the synthesis and degradation processes
in bones is almost in equilibrium, i.e. the activity of the
osteoblasts and osteoclasts is balanced. However, if this
equilibrium is disturbed in favour of the osteoclasts ancuor to the
detriment of the osteoblasts, this leads to a reduction in the bone
mass and to a negative change in the bone structure and
function.
[0003] Hitherto, bone resorption inhibitors such as oestrogens,
calcitonin and biphosphonates have primarily been used for the
treatment of metabolic bone disorders. The use of these substances
is, however, limited and also does not show the desired effect in
all cases. Compounds which have a stimulating activity on bone
synthesis and in addition contribute to an increase in an already
reduced bone mass are accordingly of especial significance for the
treatment of metabolic bone disorders.
[0004] Compounds having the rhodanine carboxylic acid structural
element are known as antidiabetics, cytostatics inflammation
inhibitors and for the treatment of cardiovascular illnesses and
bacterial infections
[0005] The parathyroid hormone (PTH), a hormone from the
parathyroid gland, is the natural ligand of the receptor and an
important regulator for the maintenance of the calcium level in the
body. PTH can stimulate bone formation or bone resorption. In this,
it acts as a regulatory hormone on a series of enzymes, inter alia,
on adenylate cydase (cAMP synthesis) and on ornithine
decarboxylase. PTH mobilizes calcium from bones in the case of
calcium deficiency, reduces calcium excretion from the kidneys and
simultaneously improves the resorption of calcium from the
intestine by an increased synthesis of 1,25-(OH).sub.2D.sub.3. A
normalization of the calcium level is achieved by the action on
these target organs. On the other hand, the incorporation of
calcium in bones is stimulated in the case of an elevated calcium
level. This osreoanabolic activity of PTH and its fragments has
been attributed to the activation of adenylate cyclase and of
cAMP-dependent protein kinases (Rixon, R. Whitfield, J. et al JMBR
9 (8) 1179-89 (1994).
[0006] Surprisingly, it has now been found that rhodanine
carboxylic acid derivatives of the present invention stimulate the
PTH receptor-mediated cAMP formation. Compounds of the present
invention are accordingly suitable for the broad treatment of
metabolic bone disorders. They can be used primarily to good effect
where the bone synthesis is disturbed, i.e. they are especially
suitable for the treatment of osteopenic disorders of the skeletal
system such as e.g. osteoporosis, inter alia, osteogenesis
imperfecta as well as for the local assistance in bone regeneration
and osteoinduction such as e.g. in orthopedic and maxillary medical
indications, in fracture healing, osteosyntheses, pseudoarthroses
and for the healing in of bone implants. However, having regard to
these properties they also find use in the prophylaxis of
osteoporosis.
[0007] By their influence on bone metabolism medicaments with the
rhodanine carboxylic acid derivatives of the present invention as
active substances furthermore form a basis for the local and
systemic treatment of rheumatoid arthritis, osteoarthritis and
degenerative arthrosis.
[0008] The object of the present invention are compounds of general
formula (I), 2
[0009] in which
[0010] m signifies a number between 0-8,
[0011] q signifies a number between 0-8
[0012] a signifies a number between 0-4
[0013] A signifies a single or double bond
[0014] R.sub.1, R.sub.2 signify hydrogen or lower alkyl, whereby
R.sub.1 and R.sub.2 can be the same or different and, when m
signifies 2-8, R.sub.1 and R.sub.2 in the group
CR.sub.1.dbd.CR.sub.2 can have various significances within the
following sequence
[0015] R.sub.3 signifies hydrogen or lower alkyl
[0016] X signifies hydrogen or --(CH.sub.2).sub.b--COR.sub.4 with
b=0-4
[0017] Y signifies hydrogen, --COR.sub.4, phenyl or indolyl
residue
[0018] R.sub.4 signifies hydroxyl, lower alkoxy or the
NR.sub.1R.sub.2 residue, whereby R.sub.1 and R.sub.2 can be the
same or different
[0019] W signifies an optionally mono- or polysubstituted saturated
or unsaturated mono-, bi- or tricyde which can contain one or more
hetero atoms,
[0020] As a rule, lower alkyl signifies linear or branched alkyl
residues with one to six carbon atoms, preferably methyl, ethyl,
propyl, i-propyl, butyl, t-butyl, pentyl, hexyl, particularly
methyl.
[0021] Alkoxy groups signify a combination of a
C.sub.1-C.sub.10-alkyl group in accordance with the above
definition with an oxygen atom, e.g. methoxy, ethoxy, propoxy,
isopropoxy, butoxy and pentoxy groups.
[0022] Under monocycle there are to be understood optionally mono-
or polysubstituted, saturated or unsaturated ring systems with 3-8,
preferably 5-7 carbon atoms, which optionally can be interrupted by
one or more hetero atoms, such as nitrogen, oxygen or sulphur,
especially the phenyl, pyridyl, pyrimidinyl, pyridazinyl,
pyrazinyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl,
morpholinyl, thiamorpholinyl, piperidinyl, piperazinyl,
tetrahydrofuranyl, tetrahydropyranyl, furyl, thiophenyl,
imidazolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl,
1,2,3-triazolyl or 1,2,4-triazolyl residue, as well as residues
such as e.g. phenyl phenyl ether, diphenylmetcne and biphenyl.
Substituents are preferably lower alkyl alkoxy,
alkoxycarbonylalkyl, alkoxycarbonyl, acetylamino,
alkoxydialkylamino, amino, dialkylamino, benzyl, benzyloxy,
benzyloxybenzyloxy, carboxyl, chiorophenylsulphanyt,
dioxymethylene, mercaptoalkyl, nitro, phenoxy, styryl and
halogen.
[0023] In the case of the bicycle set forth under W, this is
preferably a residue such as the naphthyl, tetrahydronaphthyl,
decalinyl, quinolinyl, chromane, chromene, isoquinolinyl,
tetrahydroquinolinyl, tetrahydroisoquinolinyl, indolyl,
benzimidazolyl, indazolyl, oxindolyl, benzofuranyl,
benzothiophenyl, benzothiazolyl, benzoxazolyl or purinyl residue,
especially the indolyl, naphthyl, benzimidazolyl, quinolinyl,
tetrahydroquinolinyl benzothiophenyl and benzofuranyl residue,
which optionally can be mono- or polysubstituted. Substituents are
preferably lower alkyl, alkoxy, alkoxycarbonylalkyl,
alkoxycarbonyl, acetylamino, alkoxydiakylamino, amino,
dialkylamino, benzyl, benzyloxy, benzyloxybenzyloxy, carboxyl,
chlorophenylsulphanyl, dioxymethylene, mercaptoalkyl, nitro,
phenoxy, styryl and halogen.
[0024] In the case of the tricycle set forth under W, this is
preferably a residue such as the anthracene, fluorene, dibenzofuran
or carbazole.
[0025] Compounds of formula I wherein W is phenyl or indolyl, m and
g are both 0, R.sub.3 is hydrogen and A is a double bond are
disclosed e.g. in EP-A-0677 and EP-A-0587377, however for the
treatment of Alzheimer's disease or as hypoglycemic agents.
[0026] Therefore subject of the present invention are also new
compounds of formula I 3
[0027] in which
[0028] m signifies a number between 0-8,
[0029] q signifies a number between 0-8
[0030] a signifies a number between 0-4
[0031] A signifies a single or double bond
[0032] R.sub.1, R.sub.2 signify hydrogen or lower alkyl, whereby
R.sub.1 and R.sub.2 can be the same or different and, when m
signifies 2-8, R.sub.1 and R.sub.2 in the group
CR.sub.1.dbd.CR.sub.2 can have various significances within the
following sequence
[0033] R.sub.3 signifies hydrogen or lower alkyl
[0034] X signifies hydrogen or --(CH.sub.2).sub.b--COR.sub.4 with
b=0-4
[0035] Y signifies hydrogen, --COR.sub.4, phenyl or indolyl
residue
[0036] R.sub.4 signifies hydroxyl, lower alkoxy or the
NR.sub.1R.sub.2 residue, whereby R.sub.1 and R.sub.2 can be the
same or different
[0037] W signifies an optionally mono- or polysubstituted saturated
or unsaturated mono-, bi- or tricycle which can contain one or more
hetero atoms,
[0038] whereas W is not phenyl or indolyl, if m and g are both 0,
R.sub.3 is hydrogen and A is a double bond, as well as their
physiologically compatible salts, esters, optically active forms,
racemates, tautomers, as well as derivatives which can be
metabolized in vivo to compounds of general formula (I), as well as
the use of these compounds for the production of medicaments.
[0039] Preferred are compounds of general formula I in which m
signifies a number between 0 and 4, q signifies the number 0 or 1,
a signifies a number of 0 to 4, A signifies a double bond,
R.sub.1,2 signify hydrogen or methyl, X signifies hydrogen or
--(CH.sub.2).sub.b--COR.sub.4 with b=0-2 and R.sub.4 equals
hydroxyl, methoxy or NR.sub.1R.sub.2, Y signifies hydrogen or
COR.sub.4, the phenyl or indolyl residue, R.sub.3 signifies
hydrogen or methyl and W signifies an optionally mono- or
polysubstituted benzothiophene, phenyl, benzofuran, thiophene,
naphthalene, piperidine, cyclohexenyl or biphenyl residue.
[0040] The manufacture of the compounds of general formula (I) is
possible according to methods known per se. Examples of the methods
of synthesis are set forth in Schemes 1 and 2; whereby R signifies
the group: 4 5 6
[0041] The rhodanine carboxylic acids and aldehydes used as
starting materials are either commercially available, known or can
be prepared analogously to the generally known processes.
[0042] Compounds of formula (I) can be administered (sic) in
liquid, solid or aerosol form orally, enterally, parenterally,
topically, nasally, pulmonary or rectally in all usual non-toxic
pharmaceutically acceptable carrier materials, adjuvants and
additives. The compounds of formula (I) can also be applied locally
to/in the bones (optionally with surgical intervention). The term
parenteral embraces subcutaneous, intravenous and intramuscular
delivery or infusions. Oral administration forms can be e.g.
tablets, capsules, dragees, syrups, solutions, suspensions,
emulsions, elixirs etc., which can contain one or more additives
from the following groups, such as flavourings, sweeteners,
colouring agents and preservatives. Oral administration forms
contain the active ingredient together with non-toxic,
pharmaceutically acceptable carrier materials which are suitable
for the production of tablets, capsules, dragees etc., such as e.g.
calcium carbonate, sodium carbonate, lactose, calcium phosphate or
sodium phosphate; starch, mannitol, methylcellulose, talc, highly
dispersible silicic acids, high molecular fatty acids (such as
stearic acid), groundnut oil, olive oil, parafen, miglyol,
gelatine, agar-agar, magnesium stearate, beeswax, cetyl alcohol,
lecithin, glycerol, animal and vegetable fats, solid high molecular
polymers (such as polyethylene glycol). Tablets, capsules, dragees
etc. can be provided with an appropriate coating, e.g. glyceryl
mono-stearate or glyceryl distearate, in order to prevent undesired
side effects in the gastrointestinal tract or to give a longer
duration of action by the delayed absorption in the
gastrointestinal tract As the injection medium there are preferably
used sterile injectable aqueous or oily solutions or suspensions
which contain the usual additives such as stabilizers and
solubilizers. Such additives can be e.g. water, isotonic saline,
1,3-butanediol, fatty acids (such as oleic acid), mono- and
diglycerides or miglyol. For rectal use there can be used all
suitable non-irritating additives which are solid at normal
temperatures and liquid at rectal temperatures, such as e.g. cocoa
butter and polyethylene glycol. Pharmaceutically usual carrier
media are used for application as aerosols. Creams, tinctures,
gels, solutions or suspensions etc. with the pharmaceutically usual
additives are used for external application. The dosage can depend
n a variety of factors such as mode of administration, species, age
and/or individual condition. The doses to be administered daily or
at intervals lie at 1-1000 mg/individual, preferably at 10-250
mg/individual, and can be taken at one time or divided over several
times.
[0043] The compounds of formula (I) can also be applied locally
to/in the bones (optionally with surgical intervention). The
application directly to/in the bones (optionally with surgical
intervention) can be effected locally or carrier-bonded either in
solution or suspension, conveniently by infusion or injection.
Carrier-bonded compounds of formula (I) can be administered, for
example, as gels, pastes, solids or as a coating on implants.
[0044] Biocompatible and preferably biodegradable materials are
used as the carrier. Preferably, the materials themselves also
induce wound healing or osteogenesis.
[0045] For local application it is preferred that the compounds of
formula (I) are imbedded in polymer gels or films in order to
immobilize them and to apply these preparations directly on the
site of the bone to be treated. Such polymer-based gels or films
consist, for example, of glycerine, methylcellulose, hyaluronic
acid, polyethylene oxides and/or poloxamers. Also suitable are
collagen, gelatines and alginates and are described, for example,
in WO 93/00050 and WO 93/20859. Further polymers are polylactic
acid (PLA) and copolymers of lactic acid and glycolic acid (PLPG)
(Hollinger el al., J. Biomed. Mater. Res. 17 71-82 (.1983)) as well
as the bone derivative "Demineralized Bone matrix" (DBM) (Guterman
et al. Kollagen Rel. Res. 8 419-4319 (1988). Also suitable are
polymers as are used, for example, for the adsorption of TGF.beta.
and which are described in EP-A 0 616 814 and EP-A-0 567 391 and
synthetic bone matrices in accordance with WO 91/18558.
[0046] Likewise suitable as carriers for the compounds of formula
(I) are materials which are usually used for the implantation of
bone substitutes or otherwise of therapeutically active substances.
Such carriers are based, for example, on calcium sulphate,
tricalcium phosphate, hydroxylapatite (sic) and its biodegradable
derivatives and polyanhydrides. Apart from these biodegradable
carriers there are also suitable carriers which are not
biodegradable, but which are biocompatible. Such carriers are, for
example, sintered hydroxylapatite, bioglass, aluminates or other
ceramic materials (e.g. calcium aluminium phosphate). These
materials are preferably used in combination with the biodegradable
materials, such as especially polylactic acid, hydroxylapatite,
collagen or tricalcium phosphate. Further non-degradable carriers
are described, for example, in U.S. Pat. No. 4,164,560.
[0047] It is especially preferred to use a carrier which liberates
the compounds of formula (I) continuously at the target site.
Especially suitable for this are e.g. "slow release pellets" from
Innovative Research of America, Toledo, Ohio, USA. Pellets which
release the compounds of formula (I) over several days, preferably
up to 100 days with a daily dosage of 1-10 mg/kg per day, are
especially preferred.
[0048] Preferred in the scope of the present invention are, apart
form the compounds named in the Examples and compounds derivable by
a combination of all of the significances of the substituents set
forth in the claims, the following derivatives as well as their
physiologically compatible salts, esters, optically active forms,
racemates, tautomers as well as derivatives which can be
metabolized in vivo to compounds of general formula (I), as well as
the use of these compounds for the production of medicaments,
Preferred Compounds (PC):
[0049] 1.
[5-(9H-Fluoren-2-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-yl]-a-
cetic acid
[0050] 2.
(4-Oxo-5-phenanthren-9-ylmethyl-2-thioxo-thiazolidin-3-yl)-aceti- c
acid
[0051] 3.
[5-(3-Anthracen-9-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-acetic acid
[0052] 4.
3-[5-(10-Methyl-anthracen-9-ylmethylene)-4-oxo-2-thioxo-thiazoli-
din-3-yl]-propionic acid
[0053] 5.
3-[5-(5-Furan-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo-thiazol-
idin-3-yl]-propionic acid
[0054] 6.
2-(5-Benzylidene-4-oxo-2-thioxo-thiazolidin-3-yl)-succinic acid
[0055] 7.
2-[5-(2-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pe-
ntane-dicarboxylic acid
[0056] 8.
[4-Oxo-2-thioxo-5-(2,3,4-trimethoxy-benzyl)-thiazolidin-3-yl]-ac-
etic acid
[0057] 9.
{5-[3-(2,4-Dimethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazoli-
din-3-yl}-acetic acid
[0058] 10.
3-[4-Oxo-2-thioxo-5-(2,4,5-trimethoxy-benzylidene)-thiazolidin--
3-yl]-propionic acid
[0059] 11.
3-{4-Oxo-2-thioxo-5-[3-(2,4,6-trimethoxy-phenyl)-allylidene]-th-
iazolidin-3-yl}-propionic acid
[0060] 12.
2-[5-(2,5-Dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-succinic acid
[0061] 13.
2-[5-(2-Ethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pe-
ntanedicarboxylic acid
[0062] 14.
[5-(2-Hydroxy-3-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-acetic acid
[0063] 15.
{5-[3-(3-Ethoxy-2-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-th-
iazolidin-3-yl}-acetic acid
[0064] 16.
3-[5-(2,3-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-propionic acid
[0065] 17.
3-{4-Oxo-2-thioxo-5-[3-(2,3,4-trihydroxy-phenyl)-allylidene]-th-
iazolidin-3-yl}propionic acid
[0066] 18.
2-[5-(4-Diethylamino-2-hydroxy-benzylidene)-4-oxo-2-thioxo-thia-
zolidin-3-yl]-succinic acid
[0067] 19.
2-[5-(2-Hydroxy-4-methoxy-benzylidene)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-pentanedicarboxylic acid
[0068] 20.
[5-(2-Hydroxy-5-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-acetic acid
[0069] 21.
{5-[3-(2,5-Dihydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazol-
idin-3-yl}-acetic acid
[0070] 22.
3-[5-(2-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pr-
opionic acid
[0071] 23.
3-{5-[3-(4-Methoxy-2,3-dimethyl-phenyl)-allylidene]-4-oxo-2-thi-
oxo-thiazolidin-3-yl}-propionic acid
[0072] 24.
2-[4-Oxo-2-thioxo-5-(2,4,6-trimethyl-benzylidene)-thiazolidin-3-
-yl]-succinic acid
[0073] 25.
2-[5-(2,5-Dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-pentane-dicarboxylic acid
[0074] 26.
{5-[3-(4-Methoxy-phenoxy)-benzyl]-4-oxo-2-thioxo-thiazolidin-3--
yl}-acetic acid
[0075] 27.
(5-{3-[3-(4-tert-Butyl-phenoxy)-phenyl]-allylidene}-4-oxo-2-thi-
oxo-thiazolidin-3-yl)-acetic acid
[0076] 28.
3-[4-Oxo-2-thioxo-5-(3-#pl-tolyloxy-benzylidene)-thiazolidin-3--
yl]-propionic acid
[0077] 29.
3-{5-[3-(3-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolid-
in-3-yl}-propionic acid
[0078] 30.
2-[5-(3,4-Dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-succinic acid
[0079] 31.
2-[4-Oxo-2-thioxo-5-(3,4,5-trimethoxy-benzylidene)-thiazolidin--
3-yl]-pentanedicarboxylic acid
[0080] 32.
[5-(3,5-Dimethoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acet- ic
acid
[0081] 33.
{5-[3-(3-Benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolid-
in-3-yl}-acetic acid
[0082] 34.
3-[5-(3-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-p-
ropionic acid
[0083] 35.
3-{5-[3-(3-Hydroxy-4-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-
-thiazolidin-3-yl}-propionic acid
[0084] 36.
2-[5-(3,4-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-succinic acid
[0085] 37.
2-[5-(3-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pe-
ntanedicarboxylic acid
[0086] 38.
[5-(4-Dimethylamino-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-ac-
etic acid
[0087] 39.
{5-[3-(4-Diethylamino-phenyl)-allylidene]-4-oxo-2-thioxo-thiazo-
lidin-3-yl}-acetic acid
[0088] 40.
3-[4-Oxo-5-(4-phenoxy-benzylidene)-2-thioxo-thiazolidin-3-yl]-p-
ropionic acid
[0089] 41.
3-{5-[3-(4-Methoxy-phenyl)-allylidene)-4-oxo-2-thioxo-thiazolid-
in-3-yl}-propionic acid
[0090] 42.
2-[5-(3-Benzyloxy-4-methoxy-benzylidene)-4-oxo-2-thioxo-thiazol-
idin-3-yl]-succinic acid
[0091] 43.
2-[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-pentane-dicarboxylic acid
[0092] 44.
[5-(4-Butoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid
[0093] 45.
[5-(3-Naphthalen-1-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3--
yl]-acetic acid
[0094] 46.
3-[5-(2-Methoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-propionic acid
[0095] 47.
3-{5-[3-(2-Hydroxy-naphthalen-1-yl)-allylidene]-4-oxo-2-thioxo--
thiazolidin-3-yl}-propionic acid
[0096] 48.
2-[5-(4-Methoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-succinic acid
[0097] 49.
2-(5-Naphthalen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)--
pentane-dicarboxylic acid
[0098] 50.
[5-(9-Ethyl-9H-carbazol-3-ylmethyl)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid
[0099] 51.
{5-[3-(1H-Indol-3-yl)-allylidene]-4-oxo-2-thioxo-thiazoidin-3-y-
l}-acetic acid
[0100] 52.
3-[5-(5-Methoxy-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazoli-
din-3-yl]-propionic acid
[0101] 53. 3-[5-(3-Benzo
[1,3]dioxol-5-yl-allylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-propionic acid
[0102] 54.
2-[5-(4-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-p-
entane-dicarboxylic acid
[0103] 55.
[5-(4-Hydroxy-3,5-dimethoxy-benzyl)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid
[0104] 56.
{5-[3-(3-Ethoxy-4-hydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-th-
iazolidin-3-yl}-acetic acid
[0105] 57.
3-[5-(4-Hydroxy-3,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-propionic acid
[0106] 58.
3-[5-(3-Biphenyl-4-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3--
yl]-propionic acid
[0107] 59.
2-[5-[4-Isopropyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-pentane-dicarboxylic acid
[0108] 60.
[5-(4-Ethyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid
[0109] 61.
[5-(4,4-Diphenyl-but-2-enylidene)-4-oxo-2-thioxo-thiazolidin-3--
yl]-acetic acid
[0110] 62.
3-[4-Oxo-5-[2-phenyl-propylidene)-2-thioxo-thiazolidin-3-yl]-pr-
opionic acid
[0111] 63.
3-5-(4-Methyl-5-phenyl-penta-2,4-dienylidene)-4-oxo-2-thioxo-th-
iazolidin-3-yl]-propionic acid
[0112] 64.
2-[5-[2-Hexyl-3-phenyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-
-yl]-pentane-dicarboxylic acid
[0113] 65.
[4-Oxo-5-(5-phenyl-penta-2,4-dienylidene)-2-thioxo-thiazolidin--
3-yl]-acetic acid
[0114] 66.
3-{5-[3-(2-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolid-
in-3-yl}-propionic acid
[0115] 67.
3-{5-[5-(4-Dimethylamino-phenyl)-penta-2,4-dienylidene]-4-oxo-2-
-thioxo-thiazolidin-3-yl}-propionic acid
[0116] 68.
[5-(3-Ethoxy-4-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-acetic acid
[0117] 69.
{5-[3-(4-Diethoxymethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thia-
zolidin-3-yl]-acetic acid
[0118] 70.
3-5-(4-Dimethylamino-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-t-
hiazolidin-3-yl]-propionic acid
[0119] 71.
2-[5-(2,4-Dimethoxy-3-methyl-benzylidene-1-oxo-2-thioxo-thiazol-
idin-3-yl]-pentanedicarboxylic acid
[0120] 72
[4-Oxo-5-(4-styryl-benzylidene)-2-thioxo-thiazolidin-3-yl]-aceti- c
acid
[0121] 73.
5-[4-(3-Dimethylamino-propoxy)-benzyl]-4-oxo-2-thioxo-thiazolid-
in-3-yl}-acetic acid
[0122] 74.
{5-[3-(2,4-Dihydroxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazol-
idin-3-yl}-acetic acid
[0123] 75.
3-[5-(2-Methyl-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-propionic acid
[0124] 76.
3-{5-[3-(4-Hydroxy-3-methyl-phenyl)-allylidene]-4-oxo-2-thioxo--
thiazolidin-3-yl}-propionic acid
[0125] 77.
2-[5-(2-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
pentane-dicarboxylic acid
[0126] 78.
[4-Oxo-5-(4-propoxy-benzyl)-2-thioxo-thiazolidin-3-yl]-acetic
acid
[0127] 79.
{4-Oxo-5-(3-(4-pentyloxy-phenyl)-allylidene]-2-thioxo-thiazolid-
in-3-yl}-acetic acid
[0128] 80.
3-[5-[4-Octyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
propionic acid
[0129] 81.
3-{5-[3-(5-Benzytoxy-1H-indol-3-yl)-allylidene]-4-oxo-2-thioxo--
thiazolidin-3-yl}-propionic acid
[0130] 82.
2-(5-Benzofuran-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)--
pentane-dicarboxylic acid
[0131] 83.
[4-Oxo-5-(2,3,4,5,6-pentamethyl-benzyl)-2-thioxo-thiazolidin-3--
yl]-acetic acid
[0132] 84.
{5-[3-(2-Benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolid-
in-3-yl}-acetic acid
[0133] 85.
3-[4-Oxo-2-thioxo-5-(2,3,4-trimethoxy-6-methyl-benzylidene)-thi-
azolidin-3-yl]-propionic acid
[0134] 86.
3-{5-[3-(3-Ethoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidi-
n-3-yl}-propionic acid
[0135] 87.
2-[5-(3,4-Dihydroxy-5-methoxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-pentanedicarboxylic acid
[0136] 88.
[5-(3,4-Dimethyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-aceti- c
acid
[0137] 89.
{5-[3-(4-Ethoxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-th-
iazolidin-3-yl}-acetic acid
[0138] 90.
3-[5-(4-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
propionic acid
[0139] 91.
3-{5-[3-(4-Heptydoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazol-
idin-3-yl}-propionic acid
[0140] 92.
2-(5-Benzo[1,3]dioxol-4-ylmethylene-4-oxo-2-thioxo-thiazolidin--
3-yl)-pentanedicarboxylic acid
[0141] 93.
[4-Oxo-2-thioxo-5-(2,4,5-trimethyl-benzyl)-thiazolidin-3-yl]-ac-
etic acid
[0142] 94.
{5-[3-(4-Decyloxy-phenyl)-allylidene]-4-oxo-.sup.2-thioxo-thiaz-
olidin-3-yl}-acetic acid
[0143] 95.
3-{5-[3-(4-tert-Butyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazo-
lidin-3-yl}-propionic acid
[0144] 96.
{5-[3-(4-Amino-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-
-yl}-acetic acid
[0145] 97.
3-[5-(2-tert-Butylsulphanyl-benzylidene)-4-oxo-2-thioxo-thiazol-
idin-3-yl]-propionic acid
[0146] 98.
3-{5-[3-(4-Butyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-
-3-yl}-propionic acid
[0147] 99.
2-[5-(4-tert-Butoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-pentane-dicarboxylic acid
[0148] 100.
[4-Oxo-5-(4-propyl-benzyldene)-2-thioxo-thiazolidin-3-yl]-acet- ic
acid
[0149] 101.
[5-(4-Hexyl-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid
[0150] 102.
5-[3-(4-Octyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazolidin-3-
-yl)-acetic acid
[0151] 103.
3-(5-(4-Dodecyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-propionic acid
[0152] 104.
3-{4-Oxo-5-[3-(4pentyl-phenyl)-allylidene]-2-thioxo-thiazolidi-
n-3-yl}-propionic acid
[0153] 105.
2-[5-(3-Amino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pe-
ntane-dicarboxylic acid
[0154] 106.
[3-(7-Methyl-1H-indol-3-ylmethyl)-4-oxo-2-thioxo-lLiazolidin-3-
-yl]-acetic acid
[0155] 107.
3-[4-Oxo-2-thioxo-5-(2-p-tolyl-ethylidene)-thiazolidin-3-yl]-p-
ropionic acid
[0156] 108.
3-{5-[3-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)-allylidene]-4--
oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
[0157] 109.
[5-(4-Hydroxy-2-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-acetic acid
[0158] 110.
{5-[3-(2,2-Dimethyl-chroman-6-yl)-allylidene]-4-oxo-2-thioxo-t-
hiazolidin-3-yl}-acetic acid
[0159] 111.
3-[5-(4-Isopropoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-propionic acid
[0160] 112.
2-[5-(4-Methyl-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-pentanedicarboxylic acid
[0161] 113.
{5-[3-(2,3-Dihydro-benzofuran-5-yl)-allylidene]-4-oxo-2-thioxo-
-thiazolidin-3-yl}-acetic acid
[0162] 114.
3-(4-Oxo-5-quinolin-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-p-
ropionic acid
[0163] 113.
3-{5-[5-(4-Diethylamino-phenyl)-penta-2,4-dienylidene]-4-oxo-2-
-thioxo-thiazolidin-3-yl}-propionic acid
[0164] 116.
2-[5-(4-Isobutyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-pentane-dicarboxylic acid
[0165] 117.
[5-(6-Methoxy-naphthalen-2-ylmethyl)-4-oxo-2-thioxo-thiazolidi-
n-3-yl]-acetic acid
[0166] 118.
{5-[3-(3,5-Dimethyl-phenyl)-allylidene]-4-oxo-2-thioxo-thiazol-
idin-3-yl}-acetic acid
[0167] 119.
3-[5-(1-Hydroxy-naphthalen-2-ylmethylene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-propionic acid
[0168] 120.
[5-(4-Octadecyloxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-ac-
etic acid
[0169] 121.
{5-[3-(4-Diphenylamino-phenyl)-allylidene]-4-oxo-2-thioxo-thia-
zolidin-3-yl}-acetic acid
[0170] 122.
3-[4-Oxo-2-thioxo-5-(3,4,5-trihydroxy-benzylidene)-thiazolidin-
-3-yl]-propionic acid
[0171] 123.
3-{5-[3-(4-Dimethylamino-2-methoxy-phenyl)-allylidene]-4-oxo-2-
-thioxo-thiazolidin-3-yl}-propionic acid
[0172] 124.
{5-[2-(2-Hydroxy-ethoxy)-benzyl]-4-oxo-2-thioxo-thiazolidin-3--
yl}-acetic acid
[0173] 125.
(5-{3-[4-(2-Hydroxy-ethoxy)-phenyl]-allylidene}-4-oxo-2-thioxo-
-thiazolidin-3-yl)-acetic acid
[0174] 126.
3-[5-(2-Benzyloxy-ethylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-propionic acid
[0175] 127.
3-{5-[3-(4-tert-Butoxycarbonyloxy-3-methoxy-phenyl)-allylidene-
]-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
[0176] 128.
2-[5-(2,4-Diethoxy-3-methyl-benzylidene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-pentanedicarboxylic acid
[0177] 129.
[5-(2-Benzyloxy-3-methoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-
-yl]-acetic acid
[0178] 130.
{5-[3-(4-Methanesulphonyl-phenyl)-allylidene]-4-oxo-2-thioxo-t-
hiazolidin-3-yl}-acetic acid
[0179] 131.
3-[5-(2-Hydroxy-5-methyl-benzylidene)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-propionic acid
[0180] 132.
(4-Oxo-5-thiophen-2-ylmethyl-2-thioxo-thiazolidin-3-yl)-acetic
acid
[0181] 133.
[5-(5-Naphthalen-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo-th-
iazolidin-3-yl]-acetic acid
[0182] 134.
3-[4-Oxo-5-(3-thiophen-2-yl-allylidene)-2-thioxo-thiazolidin-3-
-yl]-propionic acid
[0183] 135.
3-{5-[3-(2-[1,3]Dioxolan-2-yl-6-fluoro-phenyl)-allylidene]-4-o-
xo-2-thioxo-thiazolidin-3-yl}-propionic acid
[0184] 136.
2-[5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-pentanedicarboxylic acid
[0185] 137.
[5-(4-Benzyl-benzyl)-4-oxo-2-thioxo-thiazohidin-3-yl]-acetic
acid
[0186] 138.
{5-[5,9-Dimethyl-11-(2,6,6-trimethyl-cyclohex-1-enyl)-undeca-2-
,4,6,8,10-pentaenylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic
acid
[0187] 139.
3-[4-Oxo-5-(1H-pyrrol-2-ylmethylene)-2-thioxo-thiazolidin-3-yl-
]-propionic acid
[0188] 140.
3-[5-[3-Furan-2-yl-allylidene)-4-oxo-2-thioxo-thiazoldin-3-yl]-
-propionic acid
[0189] 141.
2-{5-[3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo-
-2-thioxo-thiazolidin-3-yl}-pentanedicarboxylic acid
[0190] 142.
(4-Oxo-5-pyridin-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-acet- ic
acid
[0191] 143.
[5-(1-Methyl-1H-pyrrol-3-ylmethyl)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid
[0192] 144.
{5-[3-(2-Hydroxy-4,6-dimethoxy-phenyl)-allylidene]-4-oxo-2-thi-
oxo-thiazolidin-3-yl}-acetic acid
[0193] 145.
3-[5-[4-Benzyloxy-2-hydroxy-benzylidene)-4-oxo-2-tioxo-thiazol-
idin-3-yl]-propiorlic acid
[0194] 146.
3-{5-[3-(5-Benzyloxy-2-hydroxy-phenyl)-allylidene]-4-oxo-2-thi-
oxo-thiazolidin-3-yl}-propionic acid
[0195] 147.
2-{5-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-benzylidene]-4-oxo-2-th-
ioxo-thiazolidin-3-yl}-pentanedicarboxylic acid
[0196] 148.
[5-(4-Benzyloxy-3,5-dihydroxy-benzyl)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-acetic acid
[0197] 149.
{5-[3-(2,5-Bis-benzyloxy-phenyl)-allylidene]-4-oxo-2-thioxo-th-
iazolidin-3-yl}acetic acid
[0198] 150.
3-[5-(4-Benzyloxy-3,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thi-
azolidin-3-yl]-propionic acid
[0199] 151.
3-[5-(3-Cyclohexyl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-propionic acid
[0200] 152.
2-{5-[3-Methyl-5-(2,6,6-trimethyl-cydohex-1-enyl)-penta-2,4-di-
enylidene]-4-oxo-2-thioxo-thiazolidin-3-yl}-pentanedicarboxylic
acid
[0201] 153.
[5-(3,4-Diethoxy-2,5-dimethyl-benzyl)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-acetic acid
[0202] 154.
{5-[5-(3,4-Diethoxy-2,3-dimethyl-phenyl)-penta-2,4-dienylidene-
]-4-oxo-2-thioxo-thiazolidin-3-yl}-acetic acid
[0203] 155.
[5-(2-Carboxymethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-
-yl]-propionic acid
[0204] 156.
2-{3-[3-(2-Carboxy-ethyl)-4-oxo-2-thioxo-thiazolidin-5-yliden]-
-propenyl}-benzoic acid
[0205] 157.
2-[5-(4-Acetoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
pentane-dicarboxylic acid
[0206] 158. Methyl
4-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethy-
l)-benzoate
[0207] 159.
4-[3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-yliden)-pro-
penyl]-benzoic acid
[0208] 160.
3-{4-[3-(2-Carboxy-ethyl)-4-oxo-2-thioxo-thiazolidn-5-ylidenme-
thyl]-phenyl}-acrylic acid
[0209] 161.
3-{4-Oxo-5-[3-(4-oxo-4H-chromen-3-yl)-allylidene]-2-thioxo-thi-
azolidin-3-yl}-propionic acid
[0210] 162.
2-[5-(4-Acetoxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-thia-
zolidin-3-yl]-pentanedicarboxylic acid
[0211] 163.
3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethyl)-benz- oic
acid
[0212] 164.
4-[3-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-yliden)-pro-
penyl]-phenyl propionate
[0213] 165.
3-[5-(5,7-Dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thi-
oxo-thiazolidin-3-yl]-propionic acid
[0214] 166.
3-{5-[3-(2-Ethoxycarbonylmethoxy-phenyl)-allylidene]-4-oxo-2-t-
hioxo-thiazolidin-3-yl}-propionic acid
[0215] 167.
2-5-(8-Carboxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazo-
lidin-3-yl]-pentanedicarboxylic acid
[0216] 168.
[5-(3,4-Diacetoxy-benzyl)-4-oxo-2-thioxo-thiazolidin-3-yl]-ace- tic
acid
[0217] 169.
{5-[3-(2-Amino-4-oxo-4H-chromen-3-yl)-allylidene]-4-oxo-2-thio-
xo-thiazolidin-3-yl}-acetic acid
[0218] 170.
3-[5-(2-Amino-6,7-dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-o-
xo-2-thioxo-thiazolidin-3-yl -propionic acid
[0219] 171. 3-{5-[3-(6-Ethyl-4-oxo-4H-cchromen-3-yl)-allylidenej
-4-oxo-2-thioxo-thiazolidin-3-yl}-propionic acid
[0220] 172.
2-[5-(6,8-Dimethyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thi-
oxo-thiazolidin-3-yl]-pentanedicarboxylic acid
[0221] 173. Methyl
2-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylmethy-
l)-benzoate
[0222] 174. Methyl
3-[3-[3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylid-
en)-propenyl]-1H-indole-6-carboxylate
[0223] 175.
3-{5-[3-(4-Acetoxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thiox-
o-thiazolidin-3-yl}-propionic acid
[0224] 176.
3-[4-Oxo-5-(3-phenyl-but-2-enylidene)-2-thioxo-thiazolidin-3-y-
l]-propionic acid
[0225] 177.
2-(4-Oxo-2-thioxo-5-(1-#pl-tolyl-ethylidene)-thiazolidin-3-yl]-
-pentane-dicarboxylic acid
[0226] 178.
{5-(1-(4-Methoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidi-
n-3-yl}-acetic acid
[0227] 179.
{5-[1-(3,4-Dichloro-phenyl)-ethyl]-4-oxo-2-thioxo-thiazolidin--
3-yl}-acetic acid
[0228] 180.
[4-Oxo-5-(3-thiophen-2-yl-but-2-enylidene)-2-thioxo-thiazolidi-
n-3-yl]-acetic acid
[0229] 181.
3-[4-Oxo-5-(11-oxo-6,11-dihydro-dibenzo[b,e]oxepin-3-ylmethyle-
ne)-2-thioxo-thiazolidin-3-yl]-propionic acid
[0230] 182.
3-{5-[3-(3,5-Dihydroxy-phenyl)-but-2-enylidene]-4-oxo-2-thioxo-
-thiazolidin-3-yl}-propionic acid
[0231] 183.
2-[5-(4-Hydroxy-3-methobenzylidene)-4-oxo-2-thioxo-thiazolidin-
-3-yl]-succinic acid
[0232] 184.
2-[5-(4-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-s-
uccinic acid
[0233] 185.
2-(4-Oxo-5-phenthylidene-2-thioxo-thiazolidin-3-yl)-succinic
acid
[0234] 186.
2-5-(2,3-Dihydro-benzo[1,4]dioxin-6-ylmethylene)-4-oxo-2-thiox-
o-thiazolidin-3-yl]-succinic acid
[0235] 187.
2-[4-Oxo-5-(4-styryl-benzylidene)-2-thioxo-thiazolidin-3-yl]-s-
uccinic acid
[0236] 188.
2-[5-(4-Allyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-succinic acid
[0237] 189.
2-[4-Oxo-5-(4-pyrrolidin-1-yl-benzylidene)-2-thioxo-thiazolidi-
n-3-yl]-succinic acid
[0238] 190.
2-(5-(3,5-Dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3--
yl]-succinic acid
[0239] 191.
2-{5-[3-(4-Methoxy-phenyl)-allylidene]-4-oxo-2-thioxo-thiazoli-
din-3-yl}-succinic acid
[0240] 192.
2-[4-Oxo-5-(4-propyl-benzylidene)-2-thioxo-thiazolidin-3-yl]-s-
uccinic acid
[0241] 193.
2-[5-(2-Ethoxy-naphthalen-1-ylmethylene)-4-oxo-2-thioxo-thiazo-
lidin-3-y]-succinic acid
[0242] 194.
2-[5-(3-Furan-2-yl-2-methyl-allylidene)-4-oxo-2-thioxo-thiazol-
idin-3-yl]-succinic acid
[0243] 195.
2-{5-[3-(4-Hydroxy-3-methoxy-phenyl)-allylidene]-4-oxo-2-thiox-
o-thiazolidin-3-yl}-succinic acid
[0244] 196.
2-{5-[3-(4-tert-Butyl-phenyl)-2-methyl-allylidene]-4-oxo-2-thi-
oxo-thiazolidin-3-yl}-succinic acid
[0245] 197.
2-{5-[3-(2-Hydroxy-ethoxy)-benzylidene]-4-oxo-2-thioxo-thiazol-
idin-3-yl}-succinic acid
[0246] 198.
2-{5-[3-(4-Hydroxy-3,5-dimethoxy-phenyl)-allylidene]-4-oxo-2-t-
hioxo-thiazolidin-3-yl}-succinic acid
[0247] 199.
2-[5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-succinic acid
[0248] 200.
2-[5-(2,4-Bis-benzyloxy-benzylidene)-4-oxo-2-thioxo-tniazolidi-
n-3-yl]-succinic acid
[0249] 201.
2-(4-Oxo-5-pyridin-2-ylmethylene-2-thioxo-thiazolidin-3-yl-suc-
cinic acid
[0250] 202.
2-[5-(4-Benzyloxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-th-
iazolidin-3-yl]-succinic acid
[0251] 203.
2-[5-(3-Biphenyl-4-yl-allylidene)-4-oxo-2-thioxo-thiazoiidin-3-
-yl]-succinic acid
[0252] 204.
2-[5-(3-Carboxy-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazoli-
din-3-yl]-succinic acid
[0253] 205.
2-[5-(4-Carboxymethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-
-3-yl]-succinic acid
[0254] 206.
2-[5-(6-Methyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thioxo--
thiazolidin-3-yl]-succinic acid
[0255] 207.
2-[5-(6-Isopropyl-4-oxo-4H-chromen-3-ylmethylene)-4-oxo-2-thio-
xo-thiazolidin-3-yl]-succinic acid
[0256] 208.
2-{5-[1-(4-Methoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazoli-
din-3-yl}-succinic acid
[0257] The following Examples show some process variants which can
be used for the synthesis of the compounds in accordance with the
invention. However, they are not intended to be a limitation of the
object of the invention. The structure of the compounds was proven
by .sup.1H- and, where necessary, by .sup.13C-NMR spectroscopy. The
purity of the substances was determined by C, H, N, P analysis as
well as by thin-layer chromatography.
EXAMPLE 1
[0258] General Process A
[0259] 5 mmol of aldehyde of the formula R--CO, wherein R has the
significance given above, and 5 mmol of
4-oxo-2-thioxo-thiazolidin-3-ylca- rboxylic acid derivative are
heated at reflux for 10 hours together with 15 mmol of sodium
acetate and 15 ml of glacial acetic acid. After cooling, the
mixture is poured into H.sub.2O. The precipitate is filtered off
under suction, rinsed with H.sub.2O and dried. For purification, it
is chromatographed over silica gel with ethyl acetate/heptane
(2:1).
[0260] The preparation of
2-(4-oxo-2-thioxo-thiazolidin-3-yl)-glutaric acid and
2-(4-oxo-2-thioxo-thiazolidin-3-yl)-succinic acid is effected
according to Chem. Heterocycl. Compd. EN 3 528-30 (1967).
[0261]
2-(5-Benzo[b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl-
)-succinic acid (1) Yellow crystals; m.p. 240.degree. C. (dec.)
[0262] 2-(5-Benzo
[b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-y-
l)-pentanedioic acid (2) Yellow crystals; m.p. 220-1.degree. C.
[0263]
2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-3-phenyl-propionic acid (3) Yellow crystals; m.p.
160.degree. C. (dec.)
[0264]
2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-3-(1H-indol-3-yl)-propionic acid (4) Orange crystals;
m.p. 140.degree. C. (dec.)
[0265]
[5-(5-Acetylamino-benzo[b]thiophen-2-ylmethylene)-4-oxo-2-thioxo-th-
iazolidin-3-yl]-acetic acid (5) Yellow crystals; m.p.
>240.degree. C.
[0266]
5-[3-(4-Methoxy-2,5-dimethyl-phenyl)-allyliden]-4-oxo-2-thioxo-thia-
zoiidin-3-yl-acetic acid (6) Red crystals; m.p. >240.degree.
C.
[0267]
5-[3-(3,5-Di-tert-butyl-4-hydroxy-phenyl)-allylidene]-4-oxo-2-thiox-
o-thiazolidin-3-yl-acetic acid (7) Yellow crystals; m.p.
>240.degree. C.
[0268]
[5-(2,3-Dihydro-benzofuran-5-ylmethylene)-4-oxo-2-thioxo-thiazolidi-
n-3-yl]-acetic acid (8) Yellow crystals; m.p. 246-7.degree. C.
[0269]
(4-Oxo-5-thiophen-2-ylmethylene-2-thioxo-thiazolidin-3-yl)-acetic
acid (9) Yellow crystals; m.p. 237-9.degree. C.
[0270] (5-Benzo
[b]thiophen-2-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)- -acetic
acid (10) Yellow crystals; m.p. 292-4.degree. C.
[0271]
[5-(3-Naphthalen-2-yl-allylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
acetic acid (11) Orange crystals; 275-7.degree. C.
[0272]
[5-(4-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid (12) Yellow crystals; m.p. 244-6.degree. C.
[0273] [5-(5-Benzo
[b]thiophen-2-yl-penta-2,4-dienylidene)-4-oxo-2-thioxo--
thiazolidin-3-yl]-acetic acid (13) Red crystals; m.p.
>240.degree. C.
[0274]
[5-(4-Hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid (14) Yellow crystals; m.p. 230-2.degree. C.
[0275]
[5-(4-Methoxy-2,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid (15) Yellow crystals; m.p. 240.degree. C.
[0276] [5-(3-Benzo
[b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiazoldin--
3-yl]-acetic acid (16) Orange crystals; m.p. >240.degree. C.
[0277]
[5-(4-Methoxy-3-methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl-
]-acetic acid (17) Yellow crystals; m.p. 235-6.degree. C.
[0278]
2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-pentanedioic acid (18) Yellow crystals; m.p.
130.degree. C. (dec.)
[0279]
[5-(4-Benzyloxy-35-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidi-
n-3-yl]-acetic acid (19) M.p. 128-30.degree. C.
[0280]
[5-(3,4-Bis-benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-
-acetic acid (20) Yellow crystals; m.p. 187-8.degree. C.
[0281]
[5-(3-Biphenyl-yl-allylidene)-4-oxo-2-thioxo-Lhiazolidin-3-yl]-acet-
ic acid (21) Orange crystals; m.p. 130.degree. C. (dec.)
[0282]
5-[1-Methyl-3-[2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-4-oxo-2-
-thioxo-thiazolidin-3-yl-acetic acid (22) Brown crystals; m.p.
100.degree. C. (dec.)
[0283]
[5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid (23) Yellow crystals; m.p. >240.degree. C.
[0284]
2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-succinic acid (24) Brown crystals; m.p. 240.degree. C.
(dec.)
[0285]
[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazol-
idin-3-yl]-acetic acid (25) Orange crystals; m.p. 120-1.degree.
C.
[0286]
[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-aceti-
c acid (26) Yellow crystals; m.p. 205-6.degree. C.
[0287]
5-[1-[3,5-Dihydroxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidin--
3-yl-acetic acid Yellow crystals; m.p. 184-8.degree. C.
[0288]
5-[-(4-Carboxymethoxy-phenyl)-ethylidene]-4-oxo-2-thioxo-thiazolidi-
n-3-yl-acetic acid (28) Yellow crystals; m.p. 111-20.degree. C.
(dec.)
[0289]
(4-Oxo-2-thioxo-5-(2,3,4-trihydroxy-benzylidene)-thiazolidin-3-yl)--
acetic acid (29) Ochre-coloured crystals; m.p. 263.degree. C.
(dec.)
[0290]
[5-(2-Hydroxy-4,6-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-
-3-yl]-acetic acid (30) Pale brown crystals; m.p. 194.degree. C.
(dec.)
[0291]
[5-(3-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-aceti-
c acid (31) Yellow crystals; m.p. 178-81.degree. C.
[0292]
3-[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pro-
pionic acid (32) Yellow crystals; m.p. 188-91.degree. C.
[0293]
2-[5-(4-Benzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-pro-
pionic acid (33) Yellow crystals; m.p. 125-8.degree. C.
[0294]
[5-(5-Benzyloxy-2-hydroxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-
-yl]-acetic acid (34) Orange crystals; m.p. 130-3.degree. C.
[0295]
5-[4-(4-Methoxy-benzyloxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin--
3-yl-acetic acid (35) Yellow crystals; m.p. 172-3.degree. C.
[0296]
5-[4-(Benzo[1,3]dioxol-5-ylmethoxy)-benzylidene]-4-oxo-2-thioxo-thi-
azolidin-3-yl-acetic acid (36) Yellow crystals; m.p. 206-7.degree.
C.
[0297]
5-[4-Oxo-2-thioxo-5-(3,4,5-trihydroxy-benzylidene)-thiazolidin-3-yl-
]-pentanecarboxylic acid (37) m.p. 212-4.degree. C.
[0298]
5-[4-(3-Methoxy-benzyloxy)-benzylidene]-4-oxo-2-thioxo-thiazolidin--
3-yl-acetic acid (38) Yellow crystals; m.p. 191-3.degree. C.
[0299]
[5-(4-Hydroxy-3,5dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-
-yl]-acetic acid (39) Orange crystals; m.p. 277-9.degree. C.
[0300]
[5-(4-Benzyloxy-3,3-dihydroxy-benzylidene)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-acetic acid (40) M.p. 178-80.degree. C.
[0301]
[5-(2,5-Bisbenzyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]--
acetic acid (41) Yellow crystals; m.p. 196-8.degree. C.
[0302]
[4-Oxo-2-thioxo-5-(3,4,5-triacetoxy-benzylidene)-thiazolidin-3-yl]--
acetic acid (42) Orange crystals; m.p. 200.degree. C. (dec.)
[0303]
5-(3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxa-2-thiox-
o-thiazolidin-3-yl-acetic acid (43) Red crystals; m.p. 252-30C.
[0304]
(5-Cyclohex-3-enybnethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-acetic
acid (44) Beige crystals; m.p. 180-2.degree. C.
[0305]
[4-Oxo-5-(3-phenyl-propylidene)-2-thioxo-thiazolidin-3-yl]-acetic
acid (45) Orange crystals; m.p. 108-11.degree. C.
[0306]
5-(3-Methyl-5-(2,6,6trimethyl-cyclohex-1-enyl)-penta-2,4-dienyliden-
]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (46) Orange crystals;
m.p. 153-5.degree. C.
[0307]
5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-3-methyl-2-thioxo-thiaz-
olidin-4-one (47) Yellow crystals; m.p. >240.degree. C.
[0308] Methyl
[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo--
thiazolidin-3-yl]-acetate (48) Yellow crystals; m.p. 165-70.degree.
C.
[0309]
2-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-N,N-diethyl-acetamide (49) Yellow crystals; m.p.
223-5.degree. C.
[0310] Methyl
5-[3-(5,6-diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo--
2-thioxo-thiazolidin-3-yl-acetate (50) Violet crystals; m.p.
211-5.degree. C.
[0311]
2-5-[3-(5,6-Diethoxy-benzo[b]thiophen-2-yl)-allylidene]-4-oxo-2-thi-
oxo-thiazolidin-3-yl-N,N-diethyl-acetamide (51) Red crystals; m.p.
210-2.degree. C.
[0312] Benzyl
4-(3-carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylidenmethyl-
)-piperidine-1-carboxylate (52) Yellow crystals; m.p. 114-5.degree.
C.
[0313]
5-[3,7-Dimethyl-9-(2,6,6-trimethyl-cyclohex-1-enyl)-nona-2,4,6,8-te-
traenylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (53)
Black (sic) crystals; m.p. 144.degree. C. (dec.)
[0314]
[5-(3,4-Dihydroxy-2,3-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazoli-
din-3-yl]-acetic acid (54) Yellow crystals; m.p. >240.degree.
C.
[0315]
[5-(3,4-Diethoxy-2,5-dimethyl-benzylidene)-4-oxo-2-thioxo-thiazolid-
in-3-yl]-acetic acid (55) Ochre coloured crystals; m.p.
185-90.degree. C.
[0316]
5-[3-(3,4-Diethoxy-2,5-dimethyl-phenyl)-allylidene]-4-oxo-2-thioxo--
thiazolidin-3-yl-acetic acid (56) Green crystals; m.p. 210.degree.
C. (dec.)
[0317]
5-[5-Methyl-7-[2,6,6-triethyl-cyclohex-1-enyl)-hepta-2,4,6-trienyli-
den]-4-oxo-2-thioxo-thiazolidin-3-yl-acetic acid (57) Black
crystals; m.p. 192-5.degree. C.
[0318]
3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl-
)-propionic acid (58) Yellow crystals; m.p. 174-6.degree. C.
[0319]
3-(4-Oxo-2-thioxo-5-(2,6,6-trimetyl-cyclohex-1-enylmethylene)-thiaz-
olidin-3-yl]-propionic acid (59) Yellow-orange crystals; m.p.
166-8.degree. C.
[0320]
3-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2-thioxo-thiaz-
olidin-3-yl]-propionic acid (60) Yellow crystals; m.p.
218-9.degree. C.
[0321]
3-(5-Naphthalen-1-ylmethylene-4-oxo-2-thioxo-thiazolidin-3-yl)-prop-
ionic acid (61) Orange crystals; m.p. 159-61.degree. C.
[0322]
3-[5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2-thioxo-thiazolidi-
n-3-yl]-propionic acid (62) Orange crystals; m.p. 246-8.degree.
C.
[0323]
[5-(4-Dibutylamino-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-ac-
etic acid (63) Orange crystals; m.p. 186-8.degree. C.
[0324]
[4-Oxo-5-(4-pentyl-benzylidene)-2-thioxo-thiazolidin-3-yl]-acetic
acid (64) Yellow crystals; m.p. 160-2.degree. C.
[0325]
[5-(3-Methoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid (65) Yellow crystals; m.p. 193-6.degree. C.
[0326]
[4-Oxo-2-thioxo-5-(2,4,5-trirmethyl-benzylidene)-thiazolidin-3-yl]--
acetic acid (66) Yellow crystals; m.p. 234-6.degree. C.
[0327]
[5-(2-Hexyloxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid (67) Yellow crystals; m.p. 148-50.degree. C.
[0328]
[5-(4-Methyl-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-acetic
acid (68) Yellow crystals; m.p. 234-6.degree. C.
[0329]
[5-(4-Methoxy-2,3-dinethyl-benzylidene)-4-oxo-2-thioxo-thiazolidin--
3-yl]-acetic acid (69) Yellow crystals; m.p. 215-7.degree. C.
[0330]
[5-(4-Hydroxy-3,5-dimethoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-
-3-yl]-acetic acid (70) Orange crystals; m.p. 238-40.degree. C.
[0331]
5-(3-Carboxymethyl-4-oxo-2-thioxo-thiazolidin-5-ylidenmethyl)-2-hyd-
roxy-benzoic acid (71) Yellow crystals; m.p. >260.degree. C.
[0332]
3-5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)-allylidene]-4-oxo-
-2-thioxo-thiazolidin-3-yl-propionic acid (72) Orange crystals;
m.p. 160-1.degree. C.
[0333]
[5-(1,4-Dihydroxy-10-methoxy-5,8-dimethyl-3,7-dioxo-1,3-dihydro-7H--
benzo[e]furo[3',4':3,4]benzo[b][1,4]dioxepin-11-ylmethylene)-4-oxo-2-thiox-
o-thiazolidin-3-yl]-acetic acid (73) Dark green crystals; m.p.
>260.degree. C.
[0334]
[5-(2-Methyl-1H-indol-3-ylmethylene)-4-oxo-2-thioxo-thiazolidin-3-y-
l]-acetic acid (74) Brown crystals; m.p. 268-70.degree. C.
[0335]
[5-(3,4-Diacetoxy-benzylidene)-4-oxo-2-thioxo-thiazolidin-3-yl]-ace-
tic acid (75) Yellow crystals; m.p. 193-53.degree. C.
EXAMPLE 2
[0336] Compounds of general formula (I) were investigated in a
suitable assay for the capability of stimulating cyclic adenylate
cyclase.
1TABLE I % cAMP Example No. Name (Test conc. 50 .mu.M) 3
2-[5-(3,5-Di-tert-butyl-4-hydrox- y-benzylidene)-4-oxo- 8
2-thioxo-thiazolidin-3-yl]-3-phenyl-propio- nic acid 13
[5-(5-Benzo[b]thiophen-2-yl-penta-2,4-dienylidene)-4- 10
oxo-2-thioxo-thiazolidin-3-yl]-acetic acid 16
[5-(3-Benzo[b]thiophen-2-yl-allylidene)-4-oxo-2- 8
thioxo-thiazolidin-3-yl]-acetic acid 22 5-[1-Methyl-3-(2,6,6-trime-
thyl-cydohex-1-enyl)- 10 allylidene]-4-oxo-2-thioxo-thiazolidin-3--
yl-acetic acid 23 [5-(3-tert-Butyl-4-hydroxy-benzylidene)-4-oxo-2-
8 thioxo-thiazolidin-3-yl]-acetic acid 25
[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo-2- 40
thioxo-thiazolidin-3-yl]-acetic acid 46 5-[3-Methyl-5-(2,6,6-trime-
thyl-cyclohex-1-enyl)-penta- 30 2,4-dienylidene]-4-oxo-2-thioxo-th-
iazolidin-3-yl-acetic acid 59 3-[4-Oxo-2-thioxo-5-(2,6,6-tr-
imethyl-cyclohex-1- 15 enylmethylene)-thiazolidin-3-yl]-propionic
acid 60 3-[5-(3,5-Di-tert-butyl-4-hydroxy-benzylidene)-4-oxo- 20
2-thioxo-thiazolidin-3-yl]-propionic acid 72
3-5-[1-Methyl-3-(2,6,6-trimethyl-cyclohex-1-enyl)- 15
allylidene]-4-oxo-2-thioxo-thiazolidin-3-yl-propionic acid
* * * * *